

References

- *Abbas A, Murphy K and Sher A.* "Functional diversity of helper T lymphocytes". *Nature*.1996; 383 (6603): 787–93.
- *Alberts, Bruce; Alexander Johnson, Julian Lewis, Martin Raff, Keith Roberts, and Peter Walters .* Molecular Biology of the Cell; Fourth Edition. New York and London: Garland Science. 2002;
- *Alexanian R, Barlogie B and Dixon D.* High-dose glucocorticoid treatment of resistant myeloma. *Ann Intern Med* 1986;105:8–11
- *Alexanian R, Barlogie B and Dixon D.* Prognosis of asymptomatic multiple myeloma. *Arch Intern Med.* 1988;148:1963-1965
- *Alexanian R, Dimopoulos MA and Hester J.* Early myeloablative therapy for multiple myeloma. *Blood .*, 1994;84:4278–4282
- *Alexanian R, Weber D and Liu F.* Differential diagnosis of monoclonal gammopathies. *Arch Pathol Lab Med.* 1999;123:108-113
- *Alexanian R.* Localized and indolent myeloma. *Blood.* 1980;56:521-526
- *Andersen MH, Schrama D, Thor Straten P and Becker JC* "Cytotoxic T cells". *J Invest Dermatol.* 2006;126 (1): 32–41
- *Arinkin MI.* Die intravitale Untersuchungsmethodik des Knochenmarks. *Folia Haematol* .1929; 38; 233-40
- *Attal M, Harousseau J and Leyvraz S.* Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. *Blood* 2006;108:3289–3294
- *Attal M, Harousseau JL and Stoppa AM.* A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. *Intergroupe Francais du Myelome. N Engl J Med* .1996;335:91–97
- *Axelsson U.* A 20-year follow-up study of 64 subjects with M-components. *Acta Med Scand.* 1986;219:519-522

- ***Badros A, Weikel D and Salama A*** . Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. *J Clin Oncol* , **2006;24:945–952**
- ***Bakkus MHC, Heirman C, Van Riet I, Van Camp B and Thielemans K***. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. *Blood* **1992; 57(2):358-63**
- ***Baldini L, Guffanti A and Cesana BM***. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. *Blood*, **1996;87:912-918**
- ***Bamias A, Kastritis E and Bamia C***. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. *J Clin Oncol* , **2005;23:8580–8587**.
- ***Barille-Nion S and Bataille R***. New insights in myeloma-induced osteolysis. *Leuk Lymphoma.*, **1997;89:789–793**.
- ***Barlogie B, Jagannath S and Vesole DH***. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. *Blood*. **2003;99(2):358-63**
- ***Barlogie B, Kyle RA and Anderson KC*** . Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. *J Clin Oncol*, **2006; 24:929–936**.
- ***Barlogie B, Smith L and Alexanian R***. Effective treatment of advanced multiple myeloma refractory to alkylating agents. *N Engl J Med*. **1984;310:1353–1356**
- ***Barlogie B, Tricot G and Anaissie E***. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. *N Engl J Med*. **2006; 354:1021–1030**.

- ***Barlogie B, Tricot GJ and van Rhee F.*** Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. *Br J Haematol.* **2006; 135:158–164.**
- ***Bataille R, Chappard D and Marcelli C.*** Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. *J Clin Oncol.* **1989;16:43-48**
- ***Bataille R, Chappard D and Marcelli C.*** Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. *Br J Haematol.* **Jun 1990;105(4):993-6**
- ***Bataille R and Sany J.*** Solitary myeloma: clinical and prognostic features of a review of 114 cases. *Cancer.* **1981;48:845-851**
- ***Bayne-Jones S and Wilson DW.*** Immunological reactions of Bence-Jones proteins: II. Differences between Bence-Jones proteins from various sources. *Bull Johns Hopkins Hosp* **1922;13:97-102**
- ***Baz R, Walker E and Choueiri TK.*** Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. *Acta Haematol.* **2007;117:162–167**
- ***Beck, Gregory; Gail S. Habicht.*** "Immunity and the Invertebrates" *Scientific American: November 1996; 60–66. Retrieved on 1 January 2007.*
- ***Bence Jones H.*** Chemical pathology. *Lancet* **1847;2:88-92**
- ***Bence Jones H.*** On the new substance occurring in the urine of a patient with mollities ossium. *Philos Trans R Soc Lond* **1848;138:55-62**
- ***Berenson JR, Crowley JJ and Grogan TM.*** Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. *Blood.* **2002;99:3163–3168**

- **Berenson JR, Lichtenstein A and Porter L.** Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. *N Engl J Med* **1996; 334:488–493.**
- **Bergsagel D.** The incidence and epidemiology of plasma cell neoplasms. *Stem Cells* .**1995;13(suppl):1–9**
- **Bergsagel DE, Sprague CC, Austin C and Griffith KM.** Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). *Cancer Chemother Rep.* **1962; 21:87–99.**
- **Bergsagel PL and Kuehl WM.** The molecular biology of multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. *Myeloma: biology and management.* 3rd ed. Philadelphia: Saunders, **2004:35-58.**
- **Bladé J, Fernández-Llamas P and Bosch F.** Renal failure in multiple myeloma: presenting features and predictors of outcome in a series of 94 patients from a single institution. *Arch Intern Med* .**1998;158:1889-1893.**
- **Bladé J, López-Guillermo A and Rozman C.** Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. *Br J Haematol* . **1992;81:391-394.**
- **Bladé J and Rosiñol L.** Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. *Curr Treat Options Oncol* . **2006; 7:237-245.**
- **Bladé J.** On the "significance" of monoclonal gammopathy of undetermined significance. *Mayo Clin Proc.* **2004; 79:855-856.**
- **Body, JJ.** Bisphosphonates for malignancy-related bone disease: current status, future developments. *Support Care Cancer.* **2006; 14:408–418.**
- **Body, JJ; Facon, T; Coleman, RE; Lipton, A and Geurs, F; Fan, M; Holloway, D; Peterson, MC; Bekker, PJ.** A study of the biological receptor activator of nuclear factor- κ B ligand inhibitor, denosumab, in patients with

multiple myeloma or bone metastases from breast cancer. **Clin Cancer Res. 2006; 12:1221–1228.**

- **Bolek TW, Marcus RD and Mendenhall NP.** Solitary plasmacytoma of bone and soft tissue. *Int J Radiat Oncol Biol Phys.* **1996;36:329-333**
- **Boon T and van der Bruggen P.** "Human tumor antigens recognized by T lymphocytes". *J Exp Med,* **1996; 183: 725–29**
- **Bowers and William.** Immunology -Chapter Thirteen: "Immunology - Chapter Thirteen: Immunoregulation". *Microbiology and Immunology On-Line Textbook.* USC School of Medicine. **2006; Retrieved on 2007-01-04.**
- **Brinch L, Hannisdal E, Foss Abrahamsen A, Kvaloy S and Langholm R.** Extramedullary plasmacytomas and solitary plasma cell tumours of bone.. **1990;44:131-134.**
- **Brittner. J. J.** Possible relationship of the oestrogenic hormones, genetic susceptibility and milk influence in the production of mammary cancer in mice. *Cancer Research.***1943; 2: 710-721**
- **Bruno B, Rotta M and Patriarca F.** A comparison of allografting with autografting for newly diagnosed myeloma. *N Engl J Med.* **2007;356:1110–1120**
- **Burnet, F.M.** 'Cancer—a biological approach', *Brit. Med. J.* **1957; 1:841–847.**
- **Burt M, Karpeh M and Ukoha O.** Medical tumors of the chest wall: solitary plasmacytoma and Ewing's sarcoma. *J Thorac Cardiovasc Surg.* **1993;105:89-96**
- **Callahan R. and Smith. G. H.** MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways. *Oncogene.* **2000; 19: 992-1001.**
- **Cancer and Leukemia Group B, National Cancer Institute (NCI), Eastern Cooperative Oncology Group.** Lenalidomide in treating patients who are undergoing Autologous Stem Cell Transplant for Multiple

Myeloma. **Bethesda, MD:** National Library of Medicine; **2000.** Accessed **May 15, 2007.**

- **Carbone PP, Kellerhouse LE and Gehan EA:** Plasmacytic myeloma: A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. **Cancer 1967; 36:842–854.**
- **Cassuto JP, Krebs BJ and Viot G:** Beta 2 microglobulin, a tumor marker of lymphoproliferative disorders. **Blood. 1978;62:166-171**
- **Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N and Parmiani G.** "T cell recognition of melanoma-associated antigens". **J Cell Physiol,2002; 182: 323–31**
- **Cavo M, Tosi P and Zamagni E.** Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. **J Clin Oncol. 2007; 25:2434–2441.**
- **Cazzola M, Messinger D and Battistel V.** Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. **Blood. 1995;86:4446–4453**
- **Cesana C, Klersy C and Barbarano L.** Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. **J Clin Oncol. 2002;20:1625-1634**
- **Chak LY, Cox RS, Bostwick DG and Hoppe TT.** Solitary plasmacytoma of bone: treatment, progression and survival. **J Clin Oncol. 1987;5:1811-1815**
- **Chandra and RK.** "Nutrition and the immune system: an introduction"of the American medical journal. **American Journal of Clinical Nutrition.1997; 66: 460S–463S**
- **Chauhan D, Singh A and Velankar M.** Distinct dynamic profiles for NPI-0052-and bortezomib-induced apoptosis in multiple myeloma. **Blood 2006; 108:970a. Abstract 3396**

- *Child JA, Morgan GJ and Davies FE.* High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. *N Engl J Med* **2003;348:1875–1883**
- *Clark WF, Stewart AK and Rock GA.* Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. *Ann Intern Med* **2005;143:777–784**
- *Coleman MP, Gatta G, Verdecchia A, Estève J, Sant M, Storm H, Allemani C, Ciccolallo L, Santaquilani M, Berrino F, and the EURO CARE Working Group.* EURO CARE-3 summary: cancer survival in Europe at the end of the 20th century. *Annals of Oncology*, **2003; 13: 581–8.**
- *Connors LH, Richardson AM, Théberge R and Costello CE.* Tabulation of transthyretin (TTR) variants as of 1/1/2000. *Amyloid* **2000 ; 18: 275–308**
- *Corradini P, Cavo M and Lokhorst H.* Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. *Blood* **2003; ;102:1927–1929**
- *Corradini P, Ladetto M and Voena C.* Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. *Blood* **1993;60:1513-1517**
- *Corwin J and Lindberg RD.* Solitary plasmacytoma of bone vs. extramedullary plasmacytoma and their relationship to multiple myeloma. *Cancer*. **1979;43:1007-1013**
- *Courtens AM, Stevens F C and Crebolder H F Philipsen H.* Longitudinal study on quality of life and social support in cancer patients. *Cancer Nursing*, **199613: 635–638**
- *Coxon FP, Thompson K and Rogers MJ.* Recent advances in understanding the mechanism of action of bisphosphonates. *Curr Opin Pharmacol*. **2006;6:307–312**

- *Crawley C, Iacobelli S and Bjorkstrand B.* Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. *Blood* **2007;109:3588–3594**
- *Crawley C, Lalancette M and Szydlo R.* Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. *Blood* **2005;105:4532–4539**
- *Delauche-Cavallier MC, Laredo JD and Wybier M.* Solitary plasmacytoma of the spine. Long-term clinical course. *Cancer.* **1988;61:1707-1714**
- *Dhodapkar MV, Jacobson JL and Gertz MA:* Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). *Blood* **2001; 98:41-48.**
- *Dighiero G, Maloum K and Desablens B.* Chlorambucil in indolent chronic lymphocytic leukemia. *N Engl J Med.* **1998 ;338:1506-1514**
- *Dimopoulos M, Weber D and Chen C.* Evaluating oral lenalidomide (Revlimid) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. *Haematologica,* **2005; 90(suppl):160. Abstract 0402.**
- *Dimopoulos MA, Galani E and Matsouka C:* Waldenstrom's macroglobulinemia. *Hematol Oncol Clin North Am* , **Dec 1999;13(6):1351-66**
- *Dimopoulos MA, Goldstein J, Fuller L, Delasalle K and Alexanian R.* Curability of solitary bone plasmacytoma. *J Clin Oncol.* **1992;10:587-590**
- *Dimopoulos MA, Moulopoulos A, Delasalle K and Alexanian R.* Solitary plasmacytoma of bone and asymptomatic multiple myeloma. *Hematol Oncol Clin North Am.* **1992 ;6:359-369**

- *Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB and Alexanian R.* Risk of disease progression in asymptomatic multiple myeloma. *Am J Med.* **1993;94:57-61**
- *Dimopoulos MA:* Waldenstrom's Macroglobulinemia-Therapy. Washington, DC: American Society of Hematology; **1999**
- *Dishaw L, Litman G and Cannon J.* "Reconstructing immune phylogeny: new perspectives". **2005; Nat Rev Immunol 5 (11): 866–79.**
- *Dispenzieri A, Rajkumar SV and Gertz MA.* Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. *Mayo Clin Proc* **2007;82:323–341**
- *Drewinko B, Alexanian R, Boyer H, Barlogie B and Rubinow SI.* The growth fraction of human myeloma cells. *Blood* **1981;36:842–854**
- *Dudeney S, Lieberman IH, Reinhardt MK and Hussein M.* Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. *J Clin Oncol*, **2002;20:2382–2387**
- *Dunn, G. P, Bruce, A. T, Ikeda, H., Old, L. J. and Schreiber, R. D.* 'Cancer immunoediting: from immunosurveillance to tumor escape', *Nature Immunology.* **2002; 3(11): 991-998.**
- *Dunn, G. P., Old, L. J. and Schreiber R. D.* 'The Three Es of Cancer Immunoediting', *Annual Review of Immunology.* **2004; 22:329-360.**
- *Durie BG, Harousseau JL and Miguel JS.* International uniform response criteria for multiple myeloma. *Leukemia* **2006;20:1467–1473**
- *Durie BG and Salmon SE.* A clinical staging system for multiple myeloma. *Cancer.* **1975;36:842-854**
- *Durie BG and Salmon SE.* A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. *Cancer,* **1975; 36:842–854.**

- **Edelman GM and Gally JA.** The nature of Bence-Jones proteins: chemical similarities to polypeptide chains of myeloma globulins and normal gamma-globulins. *J Exp Med* **1962;33(1):35-41**
- **Ellis PA and Colls BM.** Solitary plasmacytoma of bone: clinical features, treatment and survival. *Hematol Oncol.* **1992;10:207-211**
- **Erten N, Saka B and Berberoglu K.** Technetium-99m 2-methoxy-isobutyl-isonitrile uptake scintigraphy in detection of the bone marrow infiltration in multiple myeloma: correlation with MRI and other prognostic factors. *Ann Hematol.* Nov **2007; 24: 497–518.**
- **Facon T, Mary JY and Hulin C.** Randomized clinical trial comparing melphalan-prednisone (MP), MP-thalidomide (MP-THAL) and high-dose therapy using melphalan 100 mg/m² (MEL100) for newly diagnosed myeloma patients aged 65–75 years. Interim analysis of the IFM 99-06 trial on 350 patients. *Blood* **2004; 104:63a. Abstract 206**
- **Facon T, Menard JF and Michaux JL.** Prognostic factors in low tumor mass asymptomatic myeloma. *Am J Hematol.* **1995;48:71-75**
- **Fair W, Couch J and Wehner N.** "Prostatic antibacterial factor. Identity and significance. *Urology* , **1976;7 (2): 169–77**
- **Ferland JP, Alberti C and Marolleau JP.** Single versus double high dose therapy supported with autologous blood stem cell transplantation using unselected or CD34 enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma. *Hematol J,* **2003; 4(suppl):S59. Abstract P 10.2.2.**
- **Ferland JP, Ravaud P and Chevret S.** High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. *Blood,* 1998; **92:3131–3136.**
- **Fonseca R, Bailey RJ and Ahmann GJ.** Genomic abnormalities in monoclonal gammopathy of undetermined significance. *Blood*

2002;100:1417–1424

- **Fonseca R.** Cytogenetics in multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. Myeloma: biology and management. 3rd ed. Philadelphia: Saunders, **2004:67-81.**
- **Gahrton G, Svensson H and Cavo M.** Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol **2001;113:209–216**
- **Galieni P, Cavo M and Avvisati G.** Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol. **1995;6:687-691**
- **Garban F, Attal M and Michallet M.** Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood **2006;107:3474–3480**
- **Gertz M:** Waldenstrom macroglobulinemia: a review of therapy. American Journal of Hematol **2005; 79:147-57.**
- **Gertz MA, Merlini G, Treon S:** Amyloidosis and Waldenstrom Macroglobulinemia. Hematology. **2004; Abstract: 257-282.**
- **Giuliani N, Colla S and Rizzoli V.** New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol. **2004; 231: 229–236**
- **Glenn W. K., Whitaker. N. J. and Lawson. J. S.** Presence of mouse mammary tumour-like virus (MMTV) gene sequences may be associated with specific breast cancer morphology. J Clin Pathol. **2006; 60(9):1071**

- *Goel A, Carlson SK and Classic KL.* Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ 51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. *Blood.* Oct 1 2007;**109:2276–2284**
- *Goldschmidt H, Hegenbart U and Wallmeier M.* Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. *Br J Haematol* 1997; **98:736–744.**
- *Goldschmidt H.* Single vs. double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 Trial. *Haematologica* 2005; **90(suppl):38. Abstract PL8.02**
- *Govindarajan R, Jagannath S and Flick JT.* Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. *Br J Haematol* ,1996 ;**95:349–353**
- *Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L and Sorensen HF.* The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. *Haematologica* 2001;**86:1172-1179**
- *Greipp PR, San Miguel J and Durie BG.* International staging system for multiple myeloma. *J Clin Oncol* 2005;**23:3412–3420**
- *Grignani G, Gobbi PG and Formisano R.* A prognostic index for multiple myeloma. *Br J Cancer.* 1996;**73:1101-1107**
- *Guevara-Patino JA, Turk MJ, Wolchok JD and Houghton AN.* "Immunity to cancer through immune recognition of altered self: studies with melanoma". *Adv Cancer Res.*2003; **90: 157–77**
- *Hallek M, Bergsagel PL and Anderson KC.* Multiple myeloma: increasing evidence for a multistep transformation process. *Blood* 1998;**91:3-21.**
- *Hanamura I, Stewart JP and Huang Y.* Frequent gain of chromosome

band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. *Blood* . **2006;108:1724–1732**

- **Hausen. H.** Papillomaviruses Causing Cancer: Evasion for Host-Cell Control in Early Events in Carcinogenesis. *Journal of the National Cancer Institute*. **2000; 92(9):690-698.**

- **Hayakawa Y and Smyth MJ.** "Innate immune recognition and suppression of tumors". *Adv Cancer Res* , **2006;95: 293–322**
- **Hideshima T, Bergsagel PL, Kuehl WM and Anderson KC.** Advances in biology of multiple myeloma: clinical applications. *Blood* **2004;104:607-618**
- **Hideshima T, Chauhan D, Richardson P and Anderson KC.** Identification and validation of novel therapeutic targets for multiple myeloma. *J Clin Oncol* **2005 ;23:6345–6350**
- **Hill L and Embil J.** "Vaginitis: current microbiologic and clinical concepts. *CMAJ*,**1986; 134 (4): 321–31**
- **Holtmeier W and Kabelitz D.** "γδ T cells link innate and adaptive immune responses". *Chem Immunol Allergy*, **2005; 86: 151–183.**
- **International Myeloma Working Group.** Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. *Br J Haematol* **2003;121:749–757**
- **Jackson A and Scarffe JH.** Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone.**1990;26:363-371**
- **Janeway CA, Jr. et al.** *Immunobiology(6th ed.)*. **Garland Science, 2005**

- *Jemal A, Siegel R and Ward E.* Cancer statistics,. CA Cancer J Clin **2007;57:43–66**
- *Jyothirmayi R, Gangadharan VP, Nair MK and Rajan B.* Radiotherapy in the treatment of solitary plasmacytoma. Br J Radiol. **1997;70:511-516**
- *Kariyawasam H and Robinson D.* "The eosinophil: the cell and its weapons, the cytokines, its locations". *Semin Respir Crit Care Med*, **2006; 27 (2): 117–27.**
- *Katzel JA, Hari P and Vesole DH.* Multiple myeloma: charging toward a bright future. CA Cancer J Clin. **Sep-Oct 2007;354:1362-1369**
- *Katzmann JA, Clark RJ and Abraham RS.* Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem, **2002;48:1437-1444**
- *Kehry M and Hodgkin P.* "B-cell activation by helper T-cell membranes". *Crit Rev Immunol*, **1994; 14 (3–4): 221–38.**
- *Kim, R., Emi, M. and Tanabe K.* 'Cancer immunoediting from immune surveillance to immune escape', Journal of Immunology. **2007; 121(1):1-14.**
- *Knowling MA, Harwood AR and Bergsagel DE.* Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. *J Clin Oncol.* **1983;1:255-262**
- *Korngold L and Lipari R.* Multiple-myeloma proteins" III. The antigenic relationship of Bence Jones proteins to normal gamma-globulin and multiple-myeloma serum proteins. *Cancer* **1956;71:128-133**
- *Kovacs B, Maus M, Riley J, Derimanov G, Koretzky G, June C and Finkel T.* "Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation". *Proc Natl Acad Sci U S a*, **2002; 99 ;(23): 15006–11.**

- *Kumar S, Lacy MQ and Dispenzieri A.* High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. *Bone Marrow Transplant* **2004;34:161–167**
- *Kunkel HG and Tiselius A.* Electrophoresis of proteins on filter paper. *J Gen Physiol.* **1951;51:120-125**
- *Kyle RA and Rajkumar SV.* Multiple myeloma. *N Engl J Med* **2004 ;351;1860-1873**
- *Kyle RA, Beard CM, O'Fallon M and Kurland LT.* Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. *J Clin Oncol.* **1994;12:1577-1583**
- *Kyle RA, Bladé J and Rajkumar SV.* Monoclonal gammopathies of undetermined significance. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. *Myeloma: biology and management.* 3rd ed. Philadelphia: Saunders, **2004:315-52.**
- *Kyle RA, Gertz MA and Witzig TE.* Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clin Proc* **2003;78:21–33**
- *Kyle RA and Greipp P.* smoldering multiple myeloma. *N Engl J Med.* **1980;302:1347-1349**
- *Kyle RA and Lust JA.* Monoclonal gammopathies of undetermined significance. *Semin Hematol* **1989; 62(8):719-31**
- *Kyle RA and Rajkumar SV.* Monoclonal gammopathies of undetermined significance. *Hematol Oncol Clin North Am.* **1999;13:1181-1202**
- *Kyle RA, Therneau TM and Rajkumar SV.* A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med* **2002;346:564-569**
- *Kyle RA, Therneau TM and Rajkumar SV.* Prevalence of monoclonal gammopathy of undetermined significance. *N Engl J Med* **2006 ;354:1362–1369**

- **Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF and Melton LJ 3rd.** Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. *Cancer* **2004;101:2667-2674**
- **Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF and Melton LJ III.** Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. *Mayo Clin Proc* **2004 ;79:859-866**
- **Kyle RA, Yee GC and Somerfield MR.** American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. *J Clin Oncol.* **2007; 25:2464–2472.**
- **Kyle RA.** "Benign" monoclonal gammopathy -- after 20 to 35 years of follow-up. *Mayo Clin Proc.* **1993;68:26-36**
- **Kyle RA.** 'Benign' monoclonal gammopathy: a misnomer? *JAMA* **1984;251:1849-1854**
- **Kyle RA.** Monoclonal gammopathy of undetermined significance: *Med* **1978 ;64:814–826**
- **Kyle RA.** Monoclonal gammopathy of undetermined significance: natural history in 241 cases. *Am J Med* **1978; 64:814-826.**
- **Kyle RA.** Multiple myeloma: an odyssey of discovery. *Br J Haematol.* **2000; 98:2640-4.**
- **Kyle RA.** Multiple myeloma: review of 869 cases. *Mayo Clin Proc* **1975; 16(6):2060-4.**
- **Kyrtsonis MC, Mouzaki A and Maniatis A.** Mechanisms of polyclonal hypogammaglobulinemia in multiple myeloma. *Med Oncol.* **1999;16:73-77**
- **Lacy M, Gertz M and Dispenzieri A.** Lenalidomide plus dexamethasone (rev/dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. *Blood.* **2006; 108:239a. Abstract 798.**

- *Lacy MQ, Dispenzieri A and Gertz MA.* Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. *Mayo Clin Proc.* **2006** ;**81:1047–1053**
- *Lake, R.A. and van der Most R.G.* A better way for a cancer cell to die. *N. Engl. J. Med.* **2006**; **354:2503–2504.**
- *Landgren O, Gridley G and Turesson I.* Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. *Blood.* **2006**;**107:904-906**
- *Lange, T; Perras B, Fehm HL and Born J.* "Sleep Enhances the Human Antibody response to Hepatitis A Vaccination". *Psychosomatic Medicine.* **2003**; **65: 831–835.**
- *Langermans J, Hazenbos W and van Furth R.*"Antimicrobial functions of mononuclear phagocytes". *J Immunol Methods.* **1994**; **174 (1–2): 185–94.**
- *Latreille J, Barlogie B, Dosik G, Johnston DA, Drewinko B and Alexanian R.* Cellular DNA content as a marker of human multiple myeloma. *Blood* **1980**;**63:535-541**
- *Le Y, Zhou Y, Iribarren P and Wang J.* "Chemokines and chemokine receptors: their manifold roles in homeostasis and disease". *Cell Mol Immunol.* **2004**;**1 ;(2): 95–104**
- *Leboulleux M, Lelongt B and Mougenot B.* Protease resistance and binding of Ig light chains in myeloma associated tubulopathies. *Kidney Int* **1995**; **48:72-9.**
- *Lecouvet FE, Malghem J and Michaux L.* Skeletal survey in advanced multiple myeloma: radiographic versus magnetic resonance imaging survey. *Br J Haematol* , **1999**;**104:723-729**

- *Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K and Alexanian R.* Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. *Int J Radiat Oncol Biol Phys.* **1998; 441:1063-1067.**
- *Linke RP, Gärtner HV and Michels H.* High-sensitivity diagnosis of AA amyloidosis using Congo red and immunohistochemistry detects missed amyloid deposits. *J Histochem Cytochem* **1995;104:723-729**
- *Liu P, Leong T and Quam L.* Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. *Blood* **1996; 98:2640-4.**
- *Longworth LG, Shedlovsky T and MacInnes DA.* Electrophoretic patterns of normal and pathological human blood, serum, and plasma. *J Exp Med* .**1939 ;12:437-40**
- *Ludwig H, Kumpan W and Sinzinger H.* Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. *Br J Radiol.* Mar **1982;6:1041-1046**
- *Ludwig H.* Epoetin in cancer-related anaemia. *Nephrol Dial Transplant.* **1999 ;14(suppl):85–92**
- *Macintyre W.* Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. *Med Chir Trans Lond* .**1850;3;73-81**
- *MacLennan ICM, Hardie DL, Ball J and Drew M.* Antibody-secreting cells and their origins. *Clin Immunol.* **1995; 113: 224–230.**
- *Maerevoet M, Martin C and Duck L.* Osteonecrosis of the jaw and bisphosphonates. *N Engl J Med.* **2005; 353:99–102.**
- *Magee C, Vella JP, Tormey WP and Walshe JJ.* Multiple myeloma and renal failure: one center's experience. *Ren Fail.* **1998; 20: 597-606**

- **Magrangeas F, Nasser V and Avet-Loiseau H.** Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. *Blood*. **2003;101:4998-5006**
- **Maloney DG, Molina AJ and Sahebi F.** Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. *Blood*. **2003;102:3447–3454**
- **Marx RE.** Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg* **2003;61:1115–1117**
- **May R and Machesky L.** "Phagocytosis and the actin cytoskeleton". *J Cell Sci*. **2001; 114 (Pt 6): 1061–77.**
- **Mayer and Gene .** Immunology - Chapter One: Innate (non-specific) Immunity. *Microbiology and Immunology On-Line Textbook*. USC School of Medicine; **2006. Retrieved on 2007-01-01.**
- **Mayer and Gene.** Immunology - Chapter Two: Complement. *Microbiology and Immunology On-Line Textbook*. USC School of Medicine; **2006. Retrieved on 2007-01-01.**
- **Mayr NA, Wen BC and Hussey DH.** The role of radiation therapy in the treatment of solitary plasmacytomas. *Radiother Oncol*. **1990;17:293-303**
- **McElwain TJ and Powles RL.** High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. *Lancet* .**1983 ;2:822–824**
- **McLain RF and Weinstein JN.** Solitary plasmacytomas of the spine: a review of 84 cases. *J Spinal Disord*. **1989;2:69-74**
- **Medzhitov R.** "Recognition of microorganisms and activation of the immune response". *Nature*. **2007; 449 (7164): 819–26.**
- **Mendenhall CM, Thar TL and Million RR.** Solitary plasmacytoma of bone and soft tissue. *Int J Radiat Biol Phys*. **1980; 6:1497-1501.**
- **Merlini G, Baldini L and Broglia C:** Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. *Semin Oncol*. **2003; 30:211-215.**

- **Merlini G, Waldenström JG and Jayakar SD:** A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. *Blood*, **1980;98;677-681**
- **Merlini G:** Waldenström's Macroglobulinemia-Clinical Manifestations and Prognosis. Washington, DC: American Society of Hematology; **1999.**
- **Miller, SB.** "Prostaglandins in Health and Disease. **An Overview**". *Seminars in Arthritis and Rheumatism*. **2006; 36 (1): 37–49.**
- **Mitchell BS.** The proteasome—an emerging therapeutic target in cancer. *N Engl J Med* **2003 ;348:2597–2598**
- **Montoto S, Bladé J and Montserrat E.** Monoclonal gammopathy of undetermined significance. *N Engl J Med* **2002 ;346:2087-2088**
- **Moreau J, Girgis D, Hume E, Dajcs J, Austin M and O'Callaghan R.** "Phospholipase A (2) in rabbit tears: a host defense against *Staphylococcus aureus*. *Invest Ophthalmol Vis Sci*. **2001; 42 (10): 2347–54.**
- **Morel P, Monconduit M and Jacomy D:** Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. *Blood*. **2000; 96:852-58.**
- **Morgan R et al.** "Cancer regression in patients after transfer of genetically engineered lymphocytes". *Science* . **2006; 314: 126–129.**
- **Morony, S; Warmington, K; Adamu, S; Asuncion, F; Geng, Z; Grisanti, M; Tan, HL; Capparelli, C and Starnes C; Weimann B.** The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. *Endocrinology*. **2005; 146:3235–3243.**
- **Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI and Alexanian R.** Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. *J Clin Oncol*. **1993;11:1311-1315**

- *Myatt EA, Westholm FA, Weiss DT, Solomon A, Schiffer M and Stevens FJ.* Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci USA .1994; **91:3034-8.**
- *Myeloma Trialists' Collaborative Group.* Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol **2001; 129:101-106**
- *Nanni C, Zamagni E and Cavo M.* 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. **2007 ;55:74–108**
- *National Cancer Institute of Canada, National Cancer Institute (NCI), Eastern Cooperative Oncology Group.* Thalidomide and Prednisone after Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma. Bethesda, MD: National Library of Medicine; **2000. Accessed May 15, 2007.**
- *National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI).* Stem Cell Transplantation in Individuals with Multiple Myeloma. Bethesda, MD: National Library of Medicine; **2000. Accessed May 15, 2007.**
- *Nereus Pharmaceuticals, Inc.* Phase 1 Clinical Trial of NPI-0052 in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. NCT00461045. Bethesda, MD: National Library of Medicine; **2000. Accessed May 15, 2007.**
- *Neri A, Baldini L, Trecca D, Cro L, Polli E and Maiolo A.* P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood **1993;92: 187–224**
- *Niesvizky R, Jayabalan DS and Zafar F.* Lenalidomide induced myelosuppression is potentially associated with renal dysfunction in

treatment naive multiple myeloma (MM) patients receiving BiRD (Biaxin/Revlimid/Dexamethasone) combination therapy. Blood [abstract]. **Blood 2006; 108:1013a. Abstract 3549**

- *Obeid, M., Tesniere, A., Ghiringhello, F., Fimia, G.M., Apetoh, L., Perfettini, J.L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., Metivier, D., Larochette, N., van Endert, P., Ciccocanti, F., Piacentini, M., Zitvogel, L .and Kroemer, G.* Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Medicine. **2007; 13(10):54-61.**
- *Ocqueteau M, Orfao A and Almeida J.* Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients: implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol **1998;152:1655-1665**
- *Odunsi, K. and Old, L.* 'Tumor infiltrating lymphocytes: indicators of tumor-related immune responses', Cancer Immunity. **2007; 7:3.**
- *Ogawa Y and Calhoun WJ.* "The role of leukotrienes in airway inflammation.**2006; 118 (4): 789–98.**
- *Ohtani, H.* 'Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer', Cancer Immunity .**2007; 7: 4.**
- *Oken MM, Pomeroy C, Weisdorf D and Bennett JM.* Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med **1996;100:624–628**
- *O'Sullivan P, O'Dwyer H, Flint J, Munk PL and Muller NL.* Malignant chest wall neoplasms of bone and cartilage: a pictorial review of CT and MR findings. Br J Radiol. Aug **2007;354:2079–2080**
- *Paglieroni T, MacKenzie M and Gaggiano V.* Abnormalities in immunoregulatory CD5⁺ B cells precede the diagnosis of multiple myeloma. Ann N Y Acad Sci. **1992;651:486-487**

- *Palumbo A, Brinthen S and Caravita T.* Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. *Lancet.* **2006 ;367:825–831**
- *parkin DM, Bray F, Ferlay J and Pisani P.* Global cancer statistics, **2002.** *CA Cancer J Clin .2005;55:74–108*
- *Pasqualetti P, Festuccia V, Collacciani A and Casale R.* The natural history of monoclonal gammopathy of undetermined significance: a 5- to 20-year follow-up of 263 cases. *Acta Haematol .1997 ;97:174-179*
- *Pellat-Deceunynck C, Barille S and Puthier D.* Adhesion molecules on human plasma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. *Cancer Res . 1995; 23:474-81.*
- *Perlzweig WA, Delrue G and Geschicter C.* Hyperproteinemia associated with multiple myelomas: report of an unusual case. *JAMA .1928 ;23;546-552*
- *Phekoo KJ, Schey SA, Richards MA, Bevan DH Bell S, Gillett D and Møller H.* A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. *British Journal of Haematology, 2004;97:810-814*
- *Prutchi-Sagiv S, Golishevsky N and Oster HS.* Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? *Br J Haematol 2006;135:660–672*
- *Radoja S, Frey A and Vukmanovic S.* "T-cell receptor signaling events triggering granule exocytosis". *Crit Rev Immunol.2006; 26 (3): 265–90.*

- ***Rajkumar SV and Kyle RA.*** Monoclonal gammopathies of undetermined significance. *Hematol Oncol Clin North Am.* **2007;13:1181-1202**
- ***Rajkumar SV, Blood E and Vesole DH.*** Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a phase III trial coordinated by the Eastern Cooperative Oncology Group [abstract]. *Blood.* **2004; 104:63a. Abstract 205**
- ***Rajkumar SV and Blood E.*** Lenalidomide and venous thrombosis in multiple myeloma. *N Engl J Med* **2006;354:2079–2080**
- ***Rajkumar SV, Dispenzieri A, Kyle RA.*** Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. *Mayo Clin Proc* **2006; 81:693-703.**
- ***Rajkumar SV, Hussein M and Catalano J.*** A randomized double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma [abstract]. *Blood* **2006; 108:238a. Abstract 795**
- ***Rajkumar SV, Jacobus S and Callander N.*** A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. *Blood* **2006; 108:239a. Abstract 799.**
- ***Rajkumar SV, Kyle RA and Therneau TM.*** Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. *Blood* **2005;106:812–817**
- ***Rajkumar SV and Kyle RA.*** Multiple myeloma: diagnosis and treatment. *Mayo Clin Proc.* **2005;80:1371–1382**
- ***Ralph QM, Brisco MJ, Joshua DE, Brown R, Gibson J and Morley AA.*** Advancement of multiple myeloma from diagnosis through plateau phase

to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene. *Blood* .1993;71:128-133

- **Rawstron AC, Fenton JAL and Gonzalez D.** Accurate prediction of outcome for IgG and IgA monoclonal gammopathy of unknown significance patients using flow cytometry. *Haematologica* 2005; 90: Suppl 1:196-196.
- **Riccardi A, Gobbi PG and Ucci G.** Changing clinical presentation of multiple myeloma. *Eur J Cancer*. 1991; 27:1401-1405.
- **Richardson P, Lonial S and Jakubowiak A** A multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM) *Blood* .2006 ;108:1023a. Abstract 3582.
- **Richardson PG, Barlogie B and Berenson J.** A phase 2 study of bortezomib in relapsed, refractory myeloma. *N Engl J Med*. 2003;348:2609–2617
- **Richardson PG, Sonneveld P and Schuster MW.** Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 2005;352:2487–2498
- **Riedel DA and Pottern LM.** The epidemiology of multiple myeloma. *Hematol Oncol Clin North Am* 1992; 34 (1): 23–46.
- **Ries LAG, Melbert D and Krapcho M., eds.** SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Institute; 2007.
- **Roodman GD.** Pathogenesis of myeloma bone disease. *Blood*. 2004; 109:2276–2284.
- **Rosenthal N and Vogel P.** Value of the sternal puncture in the diagnosis of multiple myeloma. *J Mt Sinai Hosp* .1938;25;345-351
- **Rosen, LS; Gordon, D; Antonio, BS; Kaminski, M; Howell, A; Belch, A; Mackey, JA; Apffelstaedt, J; Hussein, M and Coleman, RE.** Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients

with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. *Cancer J.* 2001; 7:377–387.

- *Rumento G, Piazza T, Di Carlo E and Ferrini S.* "Targeting tumor-related immunosuppression for cancer immunotherapy". *Immunol Res.* 2006; 33 (2): 120–129
- *Rus H, Cudrici C and Niculescu F.* "The role of the complement system in innate immunity. *Immunol Res.* 2005; 33 (2): 103–12.
- *Ryter A.* "Relationship between ultrastructure and specific functions of macrophages. *Comp Immunol Microbiol Infect Dis.*1985; 8 (2): 119–33.
- *Sahota SS, Leo R, Hamblin TJ and Stevenson FK:* Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. *Blood,* 1996;101;675-681
- *Salminen S, Gueimonde M and Isolauri E.* "Probiotics that modify disease risk". *J Nutr .*2005;135 (5): 1294–8
- *Salzet M, Tasiemski A and Cooper E.* "Innate immunity in lophotrochozoans: the annelids". *Curr Pharm Des.* 2006; 12 (24): 3043–50.
- *Santos FR, Kozasa EH, Chauffaille Mde L ,Colleoni GW and Leite JR.* Psychosocial adaptation and quality of life among Brazilian patients with different hematological malignancies. *Journal of Psychosomatic Research,* 2006;84;430-435
- *Schindler OS, Briggs TW and Gillies SA.* Bilateral demyelinating neuropathy in a solitary lytic and sclerotic myeloma of the proximal humerus. *Int Orthop.* 1997; 21:59-61
- *Seliger B.* "Strategies of tumor immune evasion". ". *BioDrugs.* 2005; 19 (6): 347–54

- *Seliger B, Ritz U and Ferrone S* . "Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation". ". *Int J Cancer*. **2006; 118 (1): 129–38**.
- *Shaughnessy JD Jr, Haessler J and van Rhee F*. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. *Br J Haematol*. **2007 ;137:530–536**
- *Shih LY, Dunn P, Leung WM, Chen WJ and Wang PN*. Comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. *Br J Cancer*. **1995 ;71:128-133**
- *Shustik C, Belch A and Robinson S*. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. *Br J Haematol* **2007; 136:203–211**.
- *Siegel D, Jagannath S and Mazumder A*. Update on phase I clinical trial of IPI-504, a novel, water-soluble Hsp90 inhibitor, in patients with relapsed/refractory multiple myeloma (MM). *Blood*. **2006; 108:1022a. Abstract 3579**.
- *Sim R and Tsiftoglou S*. "Proteases of the complement system. *Biochem Soc Trans*. **2004; 32 (Pt 1): 21–7**
- *Singh M and O'Hagan D* . "Advances in vaccine adjuvants". *Nat Biotechnol* .**1999; 17 (11): 1075–81**.
- *Singhal S, Mehta J and Desikan R*. Antitumor activity of thalidomide in refractory multiple myeloma. *N Engl J Med* **1999 ;341:1565–1571**
- *Solly S*. Remarks on the pathology of mollities ossium with cases. *Med Chir Trans Lond* .**1844 ;27:435;461**
- *Solomon A, Weiss DT and Kattine AA*. Nephrotoxic potential of Bence Jones proteins. *N Engl J Med*. **1991; 324:1845-51**.

- *Sonneveld P, van der Holt B and Segeren C.* Intensive versus double intensive therapy in untreated multiple myeloma: update analysis of the randomized phase III Hovon 24 study. *Haematologica* .2005; **90(suppl):37. Abstract PL8.01.**
- *Spelman, K; Burns J, Nichols D, Winters N, Ottersberg S and Tenborg M.* "Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators". *Alternative Medicine reviews*. 2006;**11: 128–150**
- *Steinman, R.M. and Mellman, I.* Immunotherapy bewitched, bothered, and bewildered no more. *Science*. 2004; **305:197–200.**
- *Stewart AF.* Hypercalcemia associated with cancer. *N Engl J Med*. 2005; **352:373–379.**
- *Stewart AK, Bergsagel PL and Greipp PR.* A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. *Leukemia* 2007;**21:529–534**
- *Stewart AK and Fonseca R.* Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. *J Clin Oncol* 2005;**23:6339–6344**
- *Tan SY and Pepys MB.* Amyloidosis. *Histopathology* 1994;**18(2);350-362**
- *Tiselius A and Kabat EA.* Electrophoretic study of immune sera and purified antibody preparation. *J Exp Med*. 1939;**30;300-307**
- *Vande Berg BC, Lecouvet FE and Michaux L.* Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis. *Radiology*. Oct 1996; **201: 243-246**
- *Van de Perre P.* "Transfer of antibody via mother's milk. *Vaccine*. 2003;**21 (24): 3374–6**
- *Vejlgaard T, Abildgaard N, Jans H, Nielsen JL and Heickendorff L.* Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-

specific alkaline phosphatase and propeptides of type I and type III procollagens. *Eur J Haematol.* **1997;103:301-306**

- ***Vesole DH, Crowley JJ and Catchatourian R.*** High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. *J Clin Oncol* **1999; 17:2173–2179**
- ***Vesole DH, Tricot G and Jagannath S.*** Autotransplants in multiple myeloma: what have we learned? *Blood* **1996 ; 88:838–847**
- ***Waldenström J.*** Studies on conditions associated with disturbed gamma globulin formation (gammopathies). *Harvey Lect* **1960; 56:211-231.**
- ***Winearls CG.*** Acute myeloma kidney. *Kidney Int.* **1995; 48: 1347-61.**
- ***Wilson AT.*** Direct immunoelectrophoresis. *J Immunol* **1964;130:321-328**
- ***Wisloff F, Andersen P and Andersson TR.*** Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. I. *Eur J Haematol.* **1991;47:333-337**
- ***Wisloff F, Andersen P and Andersson TR.*** Incidence and follow-up of asymptomatic multiple myeloma. *Eur J Haematol.* **1991;47:338-341**
- ***Witzig TE, Timm M, Larson D and Greipp PR.*** Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferation disorders. *Br J Haematol.* **1999 ;104:131-137**
- ***Wright JH.*** A case of multiple myeloma. *Trans Assoc Am Phys.* **1900 ;19:89-95**
- ***Yenugu S, Hamil K, Birse C, Ruben S, French F and Hall S.*** "Antibacterial properties of the sperm-binding proteins and peptides of human epididymis 2 (HE2) family; salt sensitivity, structural dependence and their interaction with outer and cytoplasmic membranes of *Escherichia coli*. *Biochem J.* **2003; 372 (Pt 2): 473–83.**
- ***Yoshio-Hoshino N, Adachi Y and Aoki C.*** Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. *Cancer Res.* **2007; 67:871–875.**

- *Zen K and Parkos C.* "Leukocyte-epithelial interactions". *Curr Opin Cell Biol.* **2003 15 (5): 557–64.**
- *Zhan F, Hardin J and Kordsmeier B.* Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. *Blood.* **2002;99:1745-1757**
- *Zitvogel, L., Casares, N., Pequignot, M., Albert, M.L. and Kroemer, G.* The immune response against dying tumor cells. *Adv. Immunol.* **2004; 84:131–179.**
- *Zitvogel, L., Tesniere, A. and Kroemer, G.* Cancer in spite of immunosurveillance: immunoselection and immunosubversion. *Nat. Rev. Immunol.* **2006; 6:715–727.**

